Tracking Treatment Pathways in Adult Patients With Hyperkalemia.
About the study
This study aims to increase the understanding of Hyperkalemia (HK) management, treatment patterns, and the treatment decision-making process for the management of patients with HK over a period of up to 12 months. The generation of real-world evidence (RWE) to understand the treatment management decision rationale and to prospectively describe patient characteristics, treatment management patterns among patients with HK is of importance to improve adherence to guidelines and improve patient care.
The primary objective:
• Describe HK management decisions, their rationale and treatment expectations.
The secondary objective:
• Describe baseline characteristics and longitudinal clinical variables in patients with HK.
The exploratory objective:
• Describe patient awareness and satisfaction with their HK treatment management across the study period.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Patients meeting all the following inclusion criteria will be eligible for inclusion into the study:
EXCLUSION CRITERIA
- Age ≥18 years on the date of signing informed consent
- HK with serum potassium (K+) level(s) greater than 5.0 mmol/L, collected during Standard of Care, within 21 days prior to the date of enrollment*
- Provision of signed and dated informed consent
(*enrollment in study is defined as the date of Informed consent and confirmation of study eligibility, whichever occurs later).
Patients will be excluded from the study if they meet any of the following criteria:
- Concurrent participation in any trial that includes the use of K+ binders as an investigational medicinal product (IMP)
- Patients with pseudohyperkalemia
- A life expectancy of less than six months, based on physician judgement
- Acute causes of HK such as infections and/or trauma to be determined by the principal investigator
- Scheduled renal transplant
- Involvement in the planning and/or conduct of the study
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Hyperkalemia
Age (in years)
18 - 130
Participants needed
1250
Est. Completion Date
Dec 16, 2024
Treatment type
Observational
Sponsor
AstraZeneca
ClinicalTrials.gov identifier
NCT05408039
Study number
D9480R00048
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?